Shuchun Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shuchun Li has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Gaofeng Liang
State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, P.R. China
4 shared publicationsHaitao Wang
4 shared publicationsHaixia Cao
Clinical Oncology Research Center, Jiangsu Cancer Hospital Nanjing, Jiangsu Province, People's Republic of China
4 shared publicationsJianzhong Wu
Clinical Oncology Research Center, Jiangsu Cancer Hospital Nanjing, Jiangsu Province, People's Republic of China
4 shared publicationsRong Ma
Clinical Oncology Research Center, Jiangsu Cancer Hospital Nanjing, Jiangsu Province, People's Republic of China
4 shared publicationsZhongdang Xiao
4 shared publications
Latest Publications
- Open Access
Isl1 Controls Axon Pathfinding of Retinal Ganglion Cells in the Binocular Visual Pathway
Axons of retinal ganglion cells (RGCs) face a choice to project ipsilaterally or contralaterally at the optic chiasm. This decision is crucial for the establishment of binocular vision in mammals. The transcription factor ZIC2 is well known as a key determinant of ipsilateral RGC identity, however the transcriptional programs controlling contralateral RGC identity have only begun to be elucidated more recently. Here we show that inactivation of the LIM-HD transcription factor ISL1 results in an expansion of the ZIC2 + ventrotemporal (VT) domain of the retina and an increase in ipsilateral projections from outside the VT retina. RNA-Seq, gene expression and CUT&Tag analyses show that ISL1 regulates RGC laterality through a set of unique downstream effectors as well as a few common ones, as other transcription factors. Our data also show that RGC axons misrouted at the midline in Isl1 -null mutants could innervate the appropriate eye-specific regions of the dorsal lateral geniculate nucleus (dLGN) and superior colliculus (SC), in agreement with earlier studies that have shown that eye specific targeting of visual nuclei in the brain is independent of laterality decisions at the optic chiasm.
Open AccessIsl1 Controls Axon Pathfinding of Retinal Ganglion Cells in the Binocular Visual Pathway
Axons of retinal ganglion cells (RGCs) face a choice to project ipsilaterally or contralaterally at the optic chiasm. This decision is crucial for the establishment of binocular vision in mammals. The transcription factor ZIC2 is well known as a key determinant of ipsilateral RGC identity, however the transcriptional programs controlling contralateral RGC identity have only begun to be elucidated more recently. Here we show that inactivation of the LIM-HD transcription factor ISL1 results in an expansion of the ZIC2 + ventrotemporal (VT) domain of the retina and an increase in ipsilateral projections from outside the VT retina. RNA-Seq, gene expression and CUT&Tag analyses show that ISL1 regulates RGC laterality through a set of unique downstream effectors as well as a few common ones, as other transcription factors. Our data also show that RGC axons misrouted at the midline in Isl1 -null mutants could innervate the appropriate eye-specific regions of the dorsal lateral geniculate nucleus (dLGN) and superior colliculus (SC), in agreement with earlier studies that have shown that eye specific targeting of visual nuclei in the brain is independent of laterality decisions at the optic chiasm.
- Open Access
- 24 January 2024
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 44 (8)
ISL1 and POU4F1 directly interact to regulate the differentiation and survival of inner ear sensory neurons
The inner ear sensory neurons play a pivotal role in auditory processing and balance control. Though significant progresses have been made, the underlying mechanisms controlling the differentiation and survival of the inner ear sensory neurons remain largely unknown. During development, ISL1 and POU4F transcription factors are co-expressed and are required for terminal differentiation, pathfinding, axon outgrowth and survival of neurons in the central and peripheral nervous systems. However, little is understood about their functional relationship and regulatory mechanism in neural development. Here, we have knocked outIsl1orPou4f1or both in mice of both sexes. In the absence ofIsl1, the differentiation of cochleovestibular ganglion (CVG) neurons is disturbed and thatIsl1-deficient CVG neurons display defects in migration and axon pathfinding. Compound deletion ofIsl1andPou4f1causes a delay in CVG differentiation and results in a more severe CVG defect with a loss of nearly all of spiral ganglion neurons (SGNs). Moreover, ISL1 and POU4F1 interact directly in developing CVG neurons and act cooperatively as well as independently in regulating the expression of unique sets of CVG-specific genes crucial for CVG development and survival by binding to thecis-regulatory elements including the promoters ofFgf10,Pou4f2andEpha5and enhancers ofEya1andNtng2. These findings demonstrate thatIsl1andPou4f1are indispensable for CVG development and maintenance by acting epistatically to regulate genes essential for CVG development.Significance StatementInner ear neurons play critical roles in hearing and balance by transmitting auditory information in the form of electric signals from sensory hair cells to the brain. To study the genetic basis underlying their development, we identified the direct interaction and roles of transcription factors ISL1 and POU4F1 in regulating the development and maintenance of cochleovestibular ganglion (CVG) neurons. Moreover, our expression analysis uncovered thatIsl1andPou4f1are involved in the feedback regulation of CVG pioneer genes and control CVG differentiation genes. Furthermore, we identified and validated the function of thecis-regulatory elements bound by ISL1 and POU4F1 in vivo. Together, these findings provide insights into the gene regulatory network controlling the development of the inner ear neurons.
- 24 January 2024
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 44 (8)
Open AccessISL1 and POU4F1 directly interact to regulate the differentiation and survival of inner ear sensory neurons
The inner ear sensory neurons play a pivotal role in auditory processing and balance control. Though significant progresses have been made, the underlying mechanisms controlling the differentiation and survival of the inner ear sensory neurons remain largely unknown. During development, ISL1 and POU4F transcription factors are co-expressed and are required for terminal differentiation, pathfinding, axon outgrowth and survival of neurons in the central and peripheral nervous systems. However, little is understood about their functional relationship and regulatory mechanism in neural development. Here, we have knocked outIsl1orPou4f1or both in mice of both sexes. In the absence ofIsl1, the differentiation of cochleovestibular ganglion (CVG) neurons is disturbed and thatIsl1-deficient CVG neurons display defects in migration and axon pathfinding. Compound deletion ofIsl1andPou4f1causes a delay in CVG differentiation and results in a more severe CVG defect with a loss of nearly all of spiral ganglion neurons (SGNs). Moreover, ISL1 and POU4F1 interact directly in developing CVG neurons and act cooperatively as well as independently in regulating the expression of unique sets of CVG-specific genes crucial for CVG development and survival by binding to thecis-regulatory elements including the promoters ofFgf10,Pou4f2andEpha5and enhancers ofEya1andNtng2. These findings demonstrate thatIsl1andPou4f1are indispensable for CVG development and maintenance by acting epistatically to regulate genes essential for CVG development.Significance StatementInner ear neurons play critical roles in hearing and balance by transmitting auditory information in the form of electric signals from sensory hair cells to the brain. To study the genetic basis underlying their development, we identified the direct interaction and roles of transcription factors ISL1 and POU4F1 in regulating the development and maintenance of cochleovestibular ganglion (CVG) neurons. Moreover, our expression analysis uncovered thatIsl1andPou4f1are involved in the feedback regulation of CVG pioneer genes and control CVG differentiation genes. Furthermore, we identified and validated the function of thecis-regulatory elements bound by ISL1 and POU4F1 in vivo. Together, these findings provide insights into the gene regulatory network controlling the development of the inner ear neurons.
- Open Access
- 21 December 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (100) , 37429-37438
KLHL5 knockdown increases cellular sensitivity to anticancer drugs
KLHL5 knockdown increases cellular sensitivity to anticancer drugs KLHL5 knockdown increases cellular sensitivity to anticancer drugs
- 21 December 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (100) , 37429-37438
Open AccessKLHL5 knockdown increases cellular sensitivity to anticancer drugs
KLHL5 knockdown increases cellular sensitivity to anticancer drugs KLHL5 knockdown increases cellular sensitivity to anticancer drugs
- 15 December 2016
- Vol. 8 (12) , 5729-5740
Tumor profiling of co-regulated receptor tyrosine kinase and chemoresistant genes reveal different targeting options for lung and gastroesophageal cancers.
The expression of a number of genes can influence the response rates to chemotherapy while genes encoding receptor tyrosine kinases (RTKs) determine the response to most targeted cancer therapies currently used in clinics. In this study, we evaluated seven genes known to influence chemotherapeutic response (ERCC1, BRCA1, RRM1, TUBB3, STMN1, TYMS, and TOP2A) and five RTKs (EGFR, ERBB2, PDGFRB, VEGFR1 and VEGFR2) in non-small cell lung cancer (NSCLC) and esophagus cancer (EC) and the data are compared to gastric cancer (GC) data reported previously. We demonstrate significant differences in the expression profiles between different cancer types as well as heterogeneity among patients within the same cancer type. In all three cancer types, five chemoresistant genes (TOP2A, STMN1, TYMS, BRCA1 and RRM1) are coordinately up-regulated in almost all EC, approximately 90% of NSCLC and one third of GC patients. Most EC and nearly half of GC patients have increased expression of the three RTKs critical to angiogenesis (PDGFR, VEGFR1 and VEGFR2), while almost none of the NSCLC patients have elevated expression of angiogenic RTKs. A variable percentage of patients in the three cancer types show upregulation of the EGFR family RTKs, EGFR and/or ERBB2. It is of interest to note that approximately 10% of the NSCLC and GC patients are triple-negative for the chemosensitivity genes, angiogenic and EGFR RTK genes. The results suggest significant gene expression differences between different cancer types as well as heterogeneity within each cancer type and therefore different molecules should be targeted for future drug development and clinical trials.
- 15 December 2016
- Vol. 8 (12) , 5729-5740
Tumor profiling of co-regulated receptor tyrosine kinase and chemoresistant genes reveal different targeting options for lung and gastroesophageal cancers.
The expression of a number of genes can influence the response rates to chemotherapy while genes encoding receptor tyrosine kinases (RTKs) determine the response to most targeted cancer therapies currently used in clinics. In this study, we evaluated seven genes known to influence chemotherapeutic response (ERCC1, BRCA1, RRM1, TUBB3, STMN1, TYMS, and TOP2A) and five RTKs (EGFR, ERBB2, PDGFRB, VEGFR1 and VEGFR2) in non-small cell lung cancer (NSCLC) and esophagus cancer (EC) and the data are compared to gastric cancer (GC) data reported previously. We demonstrate significant differences in the expression profiles between different cancer types as well as heterogeneity among patients within the same cancer type. In all three cancer types, five chemoresistant genes (TOP2A, STMN1, TYMS, BRCA1 and RRM1) are coordinately up-regulated in almost all EC, approximately 90% of NSCLC and one third of GC patients. Most EC and nearly half of GC patients have increased expression of the three RTKs critical to angiogenesis (PDGFR, VEGFR1 and VEGFR2), while almost none of the NSCLC patients have elevated expression of angiogenic RTKs. A variable percentage of patients in the three cancer types show upregulation of the EGFR family RTKs, EGFR and/or ERBB2. It is of interest to note that approximately 10% of the NSCLC and GC patients are triple-negative for the chemosensitivity genes, angiogenic and EGFR RTK genes. The results suggest significant gene expression differences between different cancer types as well as heterogeneity within each cancer type and therefore different molecules should be targeted for future drug development and clinical trials.
- 15 August 2015
- Vol. 7 (8) , 1429-39
Delineation of gastric cancer subtypes by co-regulated expression of receptor tyrosine kinases and chemosensitivity genes.
Chemotherapy plays a key role in improving disease-free survival and overall survival of gastric cancer (GC); however, response rates are variable and a non-negligible proportion of patients undergo toxic and costly chemotherapeutic regimens without a survival benefit. Several studies have shown the existence of GC subtypes which may predict survival and respond differently to chemotherapy. It is also known that the expression level of chemotherapy-related and target therapy-related genes correlates with response to specific antitumor drugs. Nevertheless, these genes have not been considered jointly to define GC subtypes. In this study, we evaluated seven genes known to influence chemotherapeutic response (ERCC1, BRCA1, RRM1, TUBB3, STMN1, TYMS and TOP2A) and five receptor tyrosine kinases (RTKs) (EGFR, ERBB2, PDGFRB, VEGFR1 and VEGFR2). We demonstrate significant heterogeneity of gene expression among GC patients and identified four GC subtypes using the expression profiles of eight genes in two co-regulation groups: chemosensitivity (BRCA1, STMN1, TYMS and TOP2A) and RTKs (EGFR, PDGFRB, VEGFR1 and VEGFR2). The results are of immediate translational value regarding GC diagnostics and therapeutics, as many of these genes are curently widely used in relevant clinical testing.
- 15 August 2015
- Vol. 7 (8) , 1429-39
Delineation of gastric cancer subtypes by co-regulated expression of receptor tyrosine kinases and chemosensitivity genes.
Chemotherapy plays a key role in improving disease-free survival and overall survival of gastric cancer (GC); however, response rates are variable and a non-negligible proportion of patients undergo toxic and costly chemotherapeutic regimens without a survival benefit. Several studies have shown the existence of GC subtypes which may predict survival and respond differently to chemotherapy. It is also known that the expression level of chemotherapy-related and target therapy-related genes correlates with response to specific antitumor drugs. Nevertheless, these genes have not been considered jointly to define GC subtypes. In this study, we evaluated seven genes known to influence chemotherapeutic response (ERCC1, BRCA1, RRM1, TUBB3, STMN1, TYMS and TOP2A) and five receptor tyrosine kinases (RTKs) (EGFR, ERBB2, PDGFRB, VEGFR1 and VEGFR2). We demonstrate significant heterogeneity of gene expression among GC patients and identified four GC subtypes using the expression profiles of eight genes in two co-regulation groups: chemosensitivity (BRCA1, STMN1, TYMS and TOP2A) and RTKs (EGFR, PDGFRB, VEGFR1 and VEGFR2). The results are of immediate translational value regarding GC diagnostics and therapeutics, as many of these genes are curently widely used in relevant clinical testing.
- Open Access
- 7 July 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , srep11906
Quantitative and qualitative analysis of the novel antitumor 1,3,4-oxadiazole derivative (GLB) and its metabolites using HPLC-UV and UPLC-QTOF-MS
Fructose-based 3-acetyl-2,3-dihydro-1,3,4-oxadiazole (GLB) is a novel antitumor agent and belongs to glycosylated spiro-heterocyclic oxadiazole scaffold derivative. This research first reported a simple, specific, sensitive and stable high performance liquid chromatography -ultraviolet detector (HPLC-UV) method for the quantitative determination of GLB in plasma. In this method, the chromatographic separation was achieved with a reversed phase C18 column. The calibration curve for GLB was linear at 300 nm. The lower limit of quantification was 10 ng/mL. The precision, accuracy and stability of the method were validated adequately. This method was successfully applied to the pharmacokinetic study in rats for detection of GLB after oral administration. Moreover, the structures of parent compound GLB and its two major metabolites M1 and M2 were identified in plasma using an ultra performance liquid chromatography- electrospray ionization-quadrupole-time of flight- mass spectrometry (UPLC-ESI-QTOF-MS) method. Our results indicated that the di-hydroxylation (M1) and hydroxylation (M2) of GLB are the major metabolites. In conclusion, the present study provided valuable information on an analytical method for the determination of GLB and its metabolites in rats, can be used to support further developing of this antitumor agent.
- 7 July 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , srep11906
Open AccessQuantitative and qualitative analysis of the novel antitumor 1,3,4-oxadiazole derivative (GLB) and its metabolites using HPLC-UV and UPLC-QTOF-MS
Fructose-based 3-acetyl-2,3-dihydro-1,3,4-oxadiazole (GLB) is a novel antitumor agent and belongs to glycosylated spiro-heterocyclic oxadiazole scaffold derivative. This research first reported a simple, specific, sensitive and stable high performance liquid chromatography -ultraviolet detector (HPLC-UV) method for the quantitative determination of GLB in plasma. In this method, the chromatographic separation was achieved with a reversed phase C18 column. The calibration curve for GLB was linear at 300 nm. The lower limit of quantification was 10 ng/mL. The precision, accuracy and stability of the method were validated adequately. This method was successfully applied to the pharmacokinetic study in rats for detection of GLB after oral administration. Moreover, the structures of parent compound GLB and its two major metabolites M1 and M2 were identified in plasma using an ultra performance liquid chromatography- electrospray ionization-quadrupole-time of flight- mass spectrometry (UPLC-ESI-QTOF-MS) method. Our results indicated that the di-hydroxylation (M1) and hydroxylation (M2) of GLB are the major metabolites. In conclusion, the present study provided valuable information on an analytical method for the determination of GLB and its metabolites in rats, can be used to support further developing of this antitumor agent.
- 1 October 2014
- Published by Elsevier in European Journal of Pharmacology
- Vol. 740, 240-247
Anti-angiogenic effect of auranofin on HUVECs in vitro and zebrafish in vivo
- 1 October 2014
- Published by Elsevier in European Journal of Pharmacology
- Vol. 740, 240-247
Anti-angiogenic effect of auranofin on HUVECs in vitro and zebrafish in vivo
- RetractedOpen Access
- 13 August 2014
- Published by Spandidos Publications in Oncology Letters
- Vol. 8 (5) , 2043-2048
Improved ataxia telangiectasia mutated kinase inhibitor KU60019 provides a promising treatment strategy for non-invasive breast cancer
It has previously been reported that KU60019, as a highly effective radiosensitizer, inhibits the DNA damage response and blocks radiation‑induced phosphorylation of key ataxia telangiectasia mutated targets in human glioma cells. The present study investigated whether KU60019 affects cell physiological activities and strengthens the efficacy of doxorubicin‑induced DNA damage. It was demonstrated that the compound suppressed the proliferation of MCF‑7 cells and significantly increased chemosensitization. In addition, KU60019 (without doxorubicin) inhibited MCF‑7 cell motility and invasion, potentially by acting on the phosphorylated‑Akt and E‑cadherin signaling pathways. Although the majority of MCF‑7 cells were arrested at the G1/S phase following treatment with KU60019, the combination of the two compounds did not result in such a marked effect on the cell cycle. In conclusion, KU60019 is a potent chemosensitizer in combination with doxorubicin, therefore, it may provide a promising strategy for non‑invasive breast cancer.
- 13 August 2014
- Published by Spandidos Publications in Oncology Letters
- Vol. 8 (5) , 2043-2048
RetractedOpen AccessImproved ataxia telangiectasia mutated kinase inhibitor KU60019 provides a promising treatment strategy for non-invasive breast cancer
It has previously been reported that KU60019, as a highly effective radiosensitizer, inhibits the DNA damage response and blocks radiation‑induced phosphorylation of key ataxia telangiectasia mutated targets in human glioma cells. The present study investigated whether KU60019 affects cell physiological activities and strengthens the efficacy of doxorubicin‑induced DNA damage. It was demonstrated that the compound suppressed the proliferation of MCF‑7 cells and significantly increased chemosensitization. In addition, KU60019 (without doxorubicin) inhibited MCF‑7 cell motility and invasion, potentially by acting on the phosphorylated‑Akt and E‑cadherin signaling pathways. Although the majority of MCF‑7 cells were arrested at the G1/S phase following treatment with KU60019, the combination of the two compounds did not result in such a marked effect on the cell cycle. In conclusion, KU60019 is a potent chemosensitizer in combination with doxorubicin, therefore, it may provide a promising strategy for non‑invasive breast cancer.
- Open Access
- 29 May 2014
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 45 (2) , 603-610
Deep sequencing reveals complex mechanisms of microRNA deregulation in colorectal cancer
Deregulated microRNAs (miRNAs) have been reported to be of functional relevance for tumor biology. In this study, we analyzed the small RNA transcriptomes of 10 paired colorectal cancer samples using SOLiD next-generation sequencing, and generated a total of >15141000 reads. miRNA expression profiles obtained by SOLiD sequencing correlated well with quantitative PCR results. The results showed that the expression of 36 miRNAs was significantly different between the two groups of samples. Additionally, we explored the global miRNA-mRNA interactions using a statistical model. In-depth analysis reveals a diagram of extensive post-transcriptional miRNA regulations. Signaling pathways associated with the miRNA altered expression signature were identified using gene enrichment analysis. The results suggest that these microRNAs, in the aggregate, regulate signaling pathways, such as MAPK, Wnt and p53 pathways in cancer, which are known to be involved in the transformation of colorectal cancer. This evidence demonstrates that miRNAs can cooperatively regulate a given pathway and play a subtle role by regulating their target genes.
- 29 May 2014
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 45 (2) , 603-610
Open AccessDeep sequencing reveals complex mechanisms of microRNA deregulation in colorectal cancer
Deregulated microRNAs (miRNAs) have been reported to be of functional relevance for tumor biology. In this study, we analyzed the small RNA transcriptomes of 10 paired colorectal cancer samples using SOLiD next-generation sequencing, and generated a total of >15141000 reads. miRNA expression profiles obtained by SOLiD sequencing correlated well with quantitative PCR results. The results showed that the expression of 36 miRNAs was significantly different between the two groups of samples. Additionally, we explored the global miRNA-mRNA interactions using a statistical model. In-depth analysis reveals a diagram of extensive post-transcriptional miRNA regulations. Signaling pathways associated with the miRNA altered expression signature were identified using gene enrichment analysis. The results suggest that these microRNAs, in the aggregate, regulate signaling pathways, such as MAPK, Wnt and p53 pathways in cancer, which are known to be involved in the transformation of colorectal cancer. This evidence demonstrates that miRNAs can cooperatively regulate a given pathway and play a subtle role by regulating their target genes.
- Open Access
- 21 February 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (2) , e89534
Exosomes: Decreased Sensitivity of Lung Cancer A549 Cells to Cisplatin
Exosomes are small extracellular membrane vesicles of endocytic origin released by many cells that could be found in most body fluids. The main functions of exosomes are cellular communication and cellular waste clean-up. This study was conducted to determine the involvement of exosomes in the regulation of sensitivity of the lung cancer cell line A549 to cisplatin (DDP). When DDP was added to A549 cells, exosomes secretion was strengthened. Addition of the secreted exosomes to other A549 cells increased the resistance of these A549 cells to DDP. Upon exposure of A549 to DDP, the expression levels of several miRNAs and mRNAs reportedly associated with DDP sensitivity changed significantly in exosomes; these changes may mediate the resistance of A549 cells to DDP. Exosomes released by A549 cells during DDP exposure decreased the sensitivity of other A549 cells to DDP, which may be mediated by miRNAs and mRNAs exchange by exosomes via cell-to-cell communication. Although the detailed mechanism of resistance remains unclear, we believed that inhibition of exosomes formation and release might present a novel strategy for lung cancer treatment in the future.
- 21 February 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (2) , e89534
Open AccessExosomes: Decreased Sensitivity of Lung Cancer A549 Cells to Cisplatin
Exosomes are small extracellular membrane vesicles of endocytic origin released by many cells that could be found in most body fluids. The main functions of exosomes are cellular communication and cellular waste clean-up. This study was conducted to determine the involvement of exosomes in the regulation of sensitivity of the lung cancer cell line A549 to cisplatin (DDP). When DDP was added to A549 cells, exosomes secretion was strengthened. Addition of the secreted exosomes to other A549 cells increased the resistance of these A549 cells to DDP. Upon exposure of A549 to DDP, the expression levels of several miRNAs and mRNAs reportedly associated with DDP sensitivity changed significantly in exosomes; these changes may mediate the resistance of A549 cells to DDP. Exosomes released by A549 cells during DDP exposure decreased the sensitivity of other A549 cells to DDP, which may be mediated by miRNAs and mRNAs exchange by exosomes via cell-to-cell communication. Although the detailed mechanism of resistance remains unclear, we believed that inhibition of exosomes formation and release might present a novel strategy for lung cancer treatment in the future.